Earnings summaries and quarterly performance for Bio Green Med Solution.
Research analysts covering Bio Green Med Solution.
Recent press releases and 8-K filings for BGMS.
Bio Green Med Solution, Inc. Sells Plogosertib Assets to Tethra Biosciences Inc.
BGMS
M&A
- On October 6, 2025, Bio Green Med Solution, Inc. (BGMS) completed the sale of certain assets, including patent rights, related to Plogosertib to Tethra Biosciences Inc..
- Plogosertib is a polo-like kinase 1 (PLK 1) inhibitor developed for the treatment of advanced cancers and hematological malignancies.
- The purchase price for these assets includes an initial payment of $300,000 and a potential milestone payment of $170,000, contingent upon the initial dosing of the first patient in a Phase 2 Clinical Trial for the compound.
Oct 7, 2025, 1:00 PM
Quarterly earnings call transcripts for Bio Green Med Solution.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more